Lifestyle Modification in Psoriatic Patients With Fatty Liver
Response of Fatty Liver to Lifestyle Modification in Psoriasis Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Dokki
-
Giza, Dokki, Egypt
- Recruiting
- Faculty of physical therapy cairo university
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- psoriasis obese patients with coexisting fatty liver
- chronic plaque psoriasis
- patients who will not show any change in immuno-modulating psoriasis therapies for at least five months before participation in the study.
Exclusion Criteria:
- no metabolic syndrome
- no renal or cardiac or pulmonary disorders
- other types of psoriasis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: intervention group
The patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
|
for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
|
|
Active Comparator: control group
The participants of this group will receive their usual immuno-modulating therapy and continuing their usual diet and activities
|
the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psoriasis Area and Severity Index
Time Frame: It will be measured after 12 weeks
|
it is an index used to measure level and severity of psoriasis
|
It will be measured after 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dermatology Life Quality Index
Time Frame: It will be measured after 12 weeks
|
it is a questinnaire used to assess life quality in psoriasis humans
|
It will be measured after 12 weeks
|
|
triglycerides
Time Frame: It will be measured after 12 weeks
|
will measured in plasma
|
It will be measured after 12 weeks
|
|
AST
Time Frame: It will be measured after 12 weeks
|
it is plasma aspartate transaminase
|
It will be measured after 12 weeks
|
|
ALT
Time Frame: It will be measured after 12 weeks
|
it is plasma Alanine transaminase
|
It will be measured after 12 weeks
|
|
BMI
Time Frame: It will be measured after 12 weeks
|
it is body mass index
|
It will be measured after 12 weeks
|
|
waist circumference
Time Frame: It will be measured after 12 weeks
|
it will be measured at the level of umbilicus
|
It will be measured after 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P.T.REC/012/003344
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.